Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most successful fund investment fields, there is Biotechnology. Among the various public portfolio startups of the fund, we may underline GeneFormatics
We also calculated 1 valuable employee in our database.
The standard case for the fund is to invest in rounds with 10 partakers. The meaningful sponsors for the fund in investment in the same round are TaKaRa Shuzo, Perseus-Soros Biopharmaceutical Fund, OrbiMed.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2001. The fund is constantly included in less than 2 investment rounds annually.
Related Funds
Fund Name | Location |
Cooperative Research Centre (CRC) | - |
Lloyds Bank | England, London, United Kingdom |
NewFoundry | - |
PCH International | California, San Francisco, United States |
Shenzhen Qianhai Jingchao Hongfu Touzi Guanli Youxian Gongsi | China, Guangdong, Shenzhen |
Shenzhoutong Touzi Jituan | China, Guangdong, Shenzhen |
Stargazer Ventures | Oregon, Portland, United States |
University of Pennsylvania | Pennsylvania, Philadelphia, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.